**Alván 1988** Alván G, Beermann B, Hjelte L, et al (1988) Increased nonrenal clearance and increased diuretic efficiency of furosemide in cystic fibrosis. Clin Pharmacol Ther 44:436–441. https://doi.org/10.1038/clpt.1988.177

**Andreasen 1982** Andreasen F, Christensen CK, Jacobsen FK, et al (1982) The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects. European Journal of Clinical Investigation 12:247–255

**Andreasen 1981** Andreasen F, Christensen CK, Jakobsen FK, Mogensen CE (1981) The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products. Acta Pharmacol Toxicol (Copenh) 49:223–229. https://doi.org/10.1111/j.1600-0773.1981.tb00897.x

**Andreasen 1983** Andreasen F, Hansen U, Husted SE, Jansen JA (1983) The pharmacokinetics of frusemide are influenced by age. Br J Clin Pharmacol 16:391–397. https://doi.org/10.1111/j.1365-2125.1983.tb02183.x

**Andreasen 1974** Andreasen F, Jakobsen P (1974) Determination of furosemide in blood plasma and its binding to proteins in normal plasma and in plasma from patients with acute renal failure. Acta Pharmacol Toxicol (Copenh) 35:49–57. https://doi.org/10.1111/j.1600-0773.1974.tb00724.x

**Andreasen 1977** Andreasen F, Mikkelsen E (1977) Distribution, elimination and effect of furosemide in normal subjects and in patients with heart failure. Eur J Clin Pharmacol 12:15–22. https://doi.org/10.1007/BF00561400

**Avdeef 2003** Avdeef A (2003) Absorption and Drug Development: Solubility, Permeability, and Charge State

**Avdeef 2008** Avdeef A, Tsinman O (2008) Miniaturized Rotating Disk Intrinsic Dissolution Rate Measurement: Effects of Buffer Capacity in Comparisons to Traditional Wood’s Apparatus. Pharm Res 25:2613–2627. https://doi.org/10.1007/s11095-008-9679-z

**Ballester 2015** Ballester MR, Roig E, Gich I, et al (2015) Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure. Drug Des Devel Ther 9:4291–4302. https://doi.org/10.2147/DDDT.S86300

**Berthod 1999** Berthod A, Carda-Broch S, Garcia-Alvarez-Coque MC (1999) Hydrophobicity of Ionizable Compounds. A Theoretical Study and Measurements of Diuretic Octanol−Water Partition Coefficients by Countercurrent Chromatography. Anal Chem 71:879–888. https://doi.org/10.1021/ac9810563

**Bindschedler 1997** Bindschedler M, Degen P, Flesch G, et al (1997) Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 52:371–378. https://doi.org/10.1007/s002280050303

**Box 2006** Box KJ, Völgyi G, Baka E, et al (2006) Equilibrium versus kinetic measurements of aqueous solubility, and the ability of compounds to supersaturate in solution--a validation study. J Pharm Sci 95:1298–1307. https://doi.org/10.1002/jps.20613

**Branch 1977** Branch RA, Roberts CJ, Homeida M, Levine D (1977) Determinants of response to frusemide in normal subjects. Br J Clin Pharmacol 4:121–127. https://doi.org/10.1111/j.1365-2125.1977.tb00682.x

**Britz 2020** Britz H, Hanke N, Taub ME, et al (2020) Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions. Pharm Res 37:250. https://doi.org/10.1007/s11095-020-02964-z

**Ebner2015** Ebner T, Ishiguro N, Taub ME (2015) The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail. J Pharm Sci 104:3220–3228. https://doi.org/10.1002/jps.24489

**Forrey 1974** Forrey AW, Kimpel B, Blair AD, Cutler RE (1974) Furosemide concentrations in serum and urine, and its binding by serum proteins as measured fluorometrically. Clin Chem 20:152–158

**González 1982** González G, Arancibia A, Rivas MI, et al (1982) Pharmacokinetics of furosemide in patients with hepatic cirrhosis. Eur J Clin Pharmacol 22:315–320. https://doi.org/10.1007/BF00548399

**Haegeli 2007** Haegeli L, Brunner-La Rocca HP, Wenk M, et al (2007) Sublingual administration of furosemide: new application of an old drug. Br J Clin Pharmacol 64:804–809. https://doi.org/10.1111/j.1365-2125.2007.03035.x

**Hammarlund 1984** Hammarlund MM, Paalzow LK, Odlind B (1984) Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur J Clin Pharmacol 26:197–207. https://doi.org/10.1007/BF00630286

**Keller 1981** Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P (1981) Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. Eur J Clin Pharmacol 20:27–33. https://doi.org/10.1007/BF00554663

**Kelly 1974** Kelly MR, Cutler RE, Forrey AW, Kimpel BM (1974) Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther 15:178–186

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, et al (2016) Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT: pharmacometrics & systems pharmacology 5:516–531. https://doi.org/10.1002/psp4.12134

**Lambert 1983** Lambert C, Larochelle P, du Souich P (1983) Effects of phenobarbital and tobacco smoking on furosemide kinetics and dynamics in normal subjects. Clin Pharmacol Ther 34:170–175. https://doi.org/10.1038/clpt.1983.148

**Langenbucher 1972** Langenbucher F (1972) Linearization of dissolution rate curves by the Weibull distribution. J Pharm Pharmacol 24:979–981. https://doi.org/10.1111/j.2042-7158.1972.tb08930.x

**Martin 1984** Martin BK, Uihlein M, Ings RM, et al (1984) Comparative bioavailability of two furosemide formulations in humans. J Pharm Sci 73:437–441. https://doi.org/10.1002/jps.2600730404

**McNamara 1987** McNamara PJ, Foster TS, Digenis GA, et al (1987) Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study. Pharmaceutical research 4:150–153

**Meyer 2012** Meyer M, Schneckener S, Ludewig B, et al (2012) Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos 40:892–901. https://doi.org/10.1124/dmd.111.043174

**Pacifici 1987** Pacifici GM, Viani A, Schulz HU, Frercks HJ (1987) Plasma protein binding of furosemide in the elderly. Eur J Clin Pharmacol 32:199–202. https://doi.org/10.1007/BF00542196

**Ponto and Schoenwald 1990** Ponto LL, Schoenwald RD (1990) Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). Clin Pharmacokinet 18:381–408. https://doi.org/10.2165/00003088-199018050-00004

**Rakhit 1987** Rakhit A, Kochak GM, Tipnis V, Hurley ME (1987) Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 41:580–586. https://doi.org/10.1038/clpt.1987.75

**Rane 1978** Rane A, Villeneuve JP, Stone WJ, et al (1978) Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin Pharmacol Ther 24:199–207. https://doi.org/10.1002/cpt1978242199

**Rosenkranz 1992** Rosenkranz B, Lehr KH, Mackert G, Seyberth HW (1992) Metamizole-furosemide interaction study in healthy volunteers. Eur J Clin Pharmacol 42:593–598. https://doi.org/10.1007/BF00265921

**Rupp 1974** Rupp W (1974) Pharmacokinetics and pharmacodynamics of Lasix. Scott Med J 19 Suppl 1:5–13. https://doi.org/10.1177/00369330740190S103

**Schmitt 2008** Schmitt W (2008) General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 22:457–467. https://doi.org/10.1016/j.tiv.2007.09.010

**Shen 2019** Shen H, Holenarsipur VK, Mariappan TT, et al (2019) Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. J Pharmacol Exp Ther 368:136–145. https://doi.org/10.1124/jpet.118.252643

**Shoaf 2007** Shoaf SE, Bramer SL, Bricmont P, Zimmer CA (2007) Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol 50:213–222. https://doi.org/10.1097/FJC.0b013e318074f934

**Smith 1980a** Smith DE, Gee WL, Brater DC, et al (1980a) Preliminary evaluation of furosemide-probenecid interaction in humans. J Pharm Sci 69:571–575. https://doi.org/10.1002/jps.2600690526

**Smith 1980b** Smith DE, Lin ET, Benet LZ (1980b) Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. Drug Metab Dispos 8:337–342

**Söderlind 2010** Söderlind E, Karlsson E, Carlsson A, et al (2010) Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol Pharm 7:1498–1507. https://doi.org/10.1021/mp100144v

**Stopfer 2016** Stopfer P, Giessmann T, Hohl K, et al (2016) Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin. Clin Pharmacol Ther 100:259–267. https://doi.org/10.1002/cpt.406

**Stopfer 2018** Stopfer P, Giessmann T, Hohl K, et al (2018) Optimization of a drug transporter probe cocktail: potential screening tool for transporter-mediated drug-drug interactions. Br J Clin Pharmacol 84:1941–1949. https://doi.org/10.1111/bcp.13609

**Takács-Novák 2013**Takács-Novák K, Szőke V, Völgyi G, et al (2013) Biorelevant solubility of poorly soluble drugs: Rivaroxaban, furosemide, papaverine and niflumic acid. Journal of Pharmaceutical and Biomedical Analysis 83:279–285. https://doi.org/10.1016/j.jpba.2013.05.011

**Tilstone 1978** Tilstone WJ, Fine A (1978) Furosemide kinetics in renal failure. Clin Pharmacol Ther 23:644–650. https://doi.org/10.1002/cpt1978236644

**FDA 2005** U.S. FDA (2005) Clinical pharmacology and biopharmaceutics review. NDA: 21-742 - part 3. 

**FDA 2006** U.S. FDA (2006) Clinical pharmacology and biopharmaceutics review. NDA: 21-985 - part 3.

**Vaidyanathan 2008** Vaidyanathan S, Bartlett M, Dieterich HA, et al (2008) Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. Cardiovasc Ther 26:238–246. https://doi.org/10.1111/j.1755-5922.2008.00058.x

**Ventura 1996** Ventura R, Segura J (1996) Detection of diuretic agents in doping control. J Chromatogr B Biomed Appl 687:127–144. https://doi.org/10.1016/s0378-4347(96)00279-4

**Verbeeck 1982** Verbeeck RK, Patwardhan RV, Villeneuve JP, et al (1982) Furosemide disposition in cirrhosis. Clin Pharmacol Ther 31:719–725. https://doi.org/10.1038/clpt.1982.101

**Vree 1994** Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP (1994) Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. J Chromatogr B Biomed Appl 655:53–62. https://doi.org/10.1016/0378-4347(94)00093-x

**Vree 1995** Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP (1995) Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. Br J Clin Pharmacol 39:692–695

**Waller 1988** Waller ES, Crismon ML, Smith RV, et al (1988) Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. Biopharm Drug Dispos 9:211–218. https://doi.org/10.1002/bod.2510090209

**Waller 1982** Waller ES, Hamilton SF, Massarella JW, et al (1982) Disposition and absolute bioavailability of furosemide in healthy males. J Pharm Sci 71:1105–1108. https://doi.org/10.1002/jps.2600711006

**Waller 1985** Waller ES, Massarella JW, Tomkiw MS, et al (1985) Pharmacokinetics of furosemide after three different single oral doses. Biopharm Drug Dispos 6:109–117. https://doi.org/10.1002/bdd.2510060202

**Wiebe 2020** Wiebe ST, Giessmann T, Hohl K, et al (2020) Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine. Clin Pharmacokinet 59:1627–1639. https://doi.org/10.1007/s40262-020-00907-w

**Willmann 2007** Willmann S, Hohn K, Edginton A, et al (2007) Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. Journal of pharmacokinetics and pharmacodynamics 34:401–31. https://doi.org/10.1007/s10928-007-9053-5

**Wishart 2006** Wishart DS, Knox C, Guo AC, et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34:D668-672. https://doi.org/10.1093/nar/gkj067
